

Clinical Policy: Belatacept (Nulojix)

Reference Number: LA.PHAR.201

Effective Date: 09.15.22

Last Review Date: ~~11.20.25~~12.02.24

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

****Please note: This policy is for medical benefit****

Description

Belatacept (Nulojix[®]) is a selective T-cell costimulation blocker.

FDA Approved Indication(s)

Nulojix is indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant. Nulojix is to be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids.

Limitation(s) of use:

- Use Nulojix only in patients who are Epstein-Barr virus (EBV) seropositive.
- Use of Nulojix for the prophylaxis of organ rejection in transplanted organs other than kidney has not been established.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana Healthcare Connections that Nulojix is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Kidney Transplant (must meet all):

1. Prescribed for kidney transplant rejection prophylaxis;
2. Prescribed by or in consultation with a kidney transplant specialist;
3. Age \geq 18 years;
4. Request is for use in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids;
5. Member is EBV seropositive;
6. Dose does not exceed both of the following (a and b):
 - a. Initial: 10 mg/kg on Day 1 (day of transplantation) and Day 5, end of Week 2, Week 4, Week 8, and Week 12 post-transplantation;
 - b. Maintenance: 5 mg/kg at the end of Week 16 post-transplantation and every 4 weeks (\pm 3 days) thereafter.

Approval duration: ~~12~~6 months

CLINICAL POLICY
Belatacept



B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

II. Continued Therapy

A. Kidney Transplant (must meet all):

1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Nulojix for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed 5 mg/kg per infusion at the end of week 16 (after the first 6 doses) after transplantation and every 4 weeks (\pm 3 days) thereafter.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – LA.PMN.53 ~~for Medicaid, or evidence of coverage documents.~~

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

EBV: Epstein-Barr virus

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Simulect® (basiliximab)	20 mg IV within 2 hours prior to transplantation surgery, followed by 20 mg IV 4 days after transplantation	20 mg/dose

CLINICAL POLICY
Belatacept



Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
mycophenolate mofetil (Cellcept®)	1 g PO BID after transplantation 1 g IV over at least 2 hours BID initiated within 24 hours after transplantation for up to 14 days (recommended for patients unable to take an oral formulation)	2 g/day
corticosteroids (e.g., prednisone, methylprednisolone)	Varies	Varies

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): transplant recipients who are EBV seronegative or with unknown EBV serostatus due to the risk of post-transplant lymphoproliferative disorder, predominantly involving the central nervous system
- Boxed warning(s): post-transplant lymphoproliferative disorder, other malignancies, and serious infections

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Prophylaxis of organ rejection in kidney transplant recipients	<p><u>Dosing for Initial Phase:</u></p> <ul style="list-style-type: none"> • Day 1 (day of transplantation, prior to implantation) and Day 5 (approximately 96 hours after Day 1 dose): 10 mg per kg IV • End of Week 2 and Week 4 after transplantation: 10 mg per kg IV • End of Week 8 and Week 12 after transplantation: 10 mg per kg IV <p><u>Dosing for Maintenance Phase:</u> End of Week 16 after transplantation and every 4 weeks (plus or minus 3 days) thereafter: 5 mg per kg IV</p> <p>The prescribed dose must be evenly divisible by 12.5 mg in order for the dose to be prepared accurately using the reconstituted solution and provided syringe.</p>	10 mg/kg/dose for first 6 doses then 5 mg/kg/dose

VI. Product Availability

Vial: 250 mg

CLINICAL POLICY
Belatacept



VII. References

1. Nulojix Prescribing Information. Princeton, New Jersey: Bristol-Myers Squibb Company; July 2021. Available at: https://packageinserts.bms.com/pi/pi_nulojix.pdf. Accessed July ~~19, 2024~~ 15, 2025.
2. Van Gelder T, Hesselink DA. Mycophenolate revisited. Transpl Int. 2015 May;28(5):508-15. doi: 10.1111/tri.12554.
3. Malhotra D, Jethwani P. Preventing Rejection of the Kidney Transplant. J Clin Med. 2023;12(18):5938.
4. Clinical Pharmacology [database online]. Philadelphia, PA: Elsevier. Updated periodically. Available at: <http://www.clinicalkey.com/pharmacology>. Accessed August ~~14, 2024~~ 11, 2025.

Formatted: German (Germany)

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPSC Codes	Description
J0485	Injection, belatacept, 1 mg

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Converted corporate to local policy.	09.22	09.15.22
Template changes applied to other diagnoses/indications and continued therapy section. References reviewed and updated. Added verbiage this policy is for medical benefit only.	06.02.23	10.05.23
Annual review: no significant changes; COC applied as a transplant-related indication in continued therapy section; references reviewed and updated.	04.15.24	07.10.24
4Q 2024 annual review: no significant changes; references reviewed and updated.	12.02.24	<u>02.24.25</u>
<u>Annual review: revised initial approval durations to 12 months; references reviewed and updated</u>	<u>11.20.25</u>	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

CLINICAL POLICY

Belatacept



The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2025 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.